PolyPid (PYPD) Stock Forecast, Price Target & Predictions
PYPD Stock Forecast
PolyPid stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PYPD Analyst Ratings
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 06, 2022 | Raymond James | - | Outperform | Downgrade |
Sep 02, 2022 | Guggenheim | - | Neutral | Upgrade |
Aug 11, 2022 | BMO Capital | Outperform | Outperform | Hold |
PolyPid Financial Forecast
PolyPid Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
PolyPid EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
PolyPid Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-3.32M | $-3.98M | $-4.35M | $-5.17M | $-5.66M | $-5.14M | $-6.53M |
High Forecast | $-3.32M | $-3.98M | $-4.35M | $-5.17M | $-5.66M | $-5.14M | $-6.53M |
Low Forecast | $-3.32M | $-3.98M | $-4.35M | $-5.17M | $-5.66M | $-5.14M | $-6.53M |
Surprise % | - | - | - | - | - | - | - |
PolyPid SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
PolyPid EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.66 | $-0.79 | $-0.87 | $-1.03 | $-1.13 | $-1.02 | $-1.30 |
High Forecast | $-0.66 | $-0.79 | $-0.87 | $-1.03 | $-1.13 | $-1.02 | $-1.30 |
Low Forecast | $-0.66 | $-0.79 | $-0.87 | $-1.03 | $-1.13 | $-1.02 | $-1.30 |
Surprise % | - | - | - | - | - | - | - |
PolyPid Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
INAB | IN8bio | $0.30 | $14.00 | 4566.67% | Buy |
KPRX | Kiora Pharmaceuticals | $3.68 | $120.00 | 3160.87% | Buy |
BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
PYPD | PolyPid | $3.33 | $25.00 | 650.75% | Buy |
VACC | Barinthus Biotherapeutics | $5.00 | $22.00 | 340.00% | - |
VRPX | Virpax Pharmaceuticals | $0.71 | $3.00 | 322.54% | - |
INMB | INmune Bio | $6.25 | $22.00 | 252.00% | Buy |
CUE | Cue Biopharma | $1.49 | $5.00 | 235.57% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
PYXS | Pyxis Oncology | $3.80 | $9.00 | 136.84% | Buy |
ANIX | Anixa Biosciences | $3.45 | $7.50 | 117.39% | Buy |
ZURA | Zura Bio | $4.37 | $5.00 | 14.42% | Buy |
EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
PYPD Forecast FAQ
Is PolyPid a good buy?
Yes, according to 3 Wall Street analysts, PolyPid (PYPD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of PYPD's total ratings.
What are PolyPid's analysts' financial forecasts?
PolyPid's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-17.339M (high $-17.339M, low $-17.339M), average SG&A $0 (high $0, low $0), and average EPS is $-3.451 (high $-3.451, low $-3.451). PYPD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-16.828M (high $-16.828M, low $-16.828M), average SG&A $0 (high $0, low $0), and average EPS is $-3.349 (high $-3.349, low $-3.349).